Unibest

Pharmaceutical intermediates

Daridorexant Hydrochloride Intermediates

4 pharmaceutical intermediates for Daridorexant Hydrochloride. Indication: Sleep onset and sleep disorders.

提交项目All intermediates

About Daridorexant Hydrochloride

Originator
Actelion Pharmaceuticals Ltd
Indication
Sleep onset and sleep disorders
Approved Date
04/07/2022
NCE Patent
04/07/2027
DS/DP
06/12/2033

Available intermediates

4 intermediates currently listed for Daridorexant Hydrochloride. Request specifications, documentation or a quotation for any item below.

Daridorexant Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Chloro-3-Methylbenzene-1,2- diaMine hydrochloride1087743-89-2//
2-Methyl-L-proline Methyl ester hydrochloride220060-08-2//
(S)-2-Methylpyrrolidine-2- carboxylic acid hydrochloride1508261-86-6//
5-methoxy-2-(2H-1,2,3-triazol-2- yl)benzoic acid1293284-55-5//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDabrafenib MesylateDacomitinibDanicopanDapagliflozinDarolutamideDasatinib Hydrate

Building toward Daridorexant Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →